Quinidine (DB00908): A Comprehensive Pharmacological and Clinical Monograph

1.0 Executive Summary

Quinidine is a naturally derived cinchona alkaloid and the prototypical Class IA antiarrhythmic agent, holding a unique and storied place in the history of pharmacology.[1] As the dextrorotatory stereoisomer of the antimalarial drug quinine, quinidine itself possesses a dual therapeutic legacy, having been used historically for the treatment of both cardiac arrhythmias and malaria.[1] Its primary mechanism of action involves the complex blockade of multiple cardiac ion channels, most notably the fast inward sodium current (

INa​) and several repolarizing potassium currents (e.g., IKr​, IKs​). This multi-channel blockade is the foundation for both its therapeutic efficacy in terminating reentrant arrhythmias and its significant, life-threatening proarrhythmic risk, particularly the prolongation of the QT interval and the induction of Torsades de Pointes.[1]

The clinical application of quinidine has undergone a profound paradigm shift. Once a first-line agent for common arrhythmias such as atrial fibrillation, its use was drastically curtailed following the emergence of a clear safety signal in the form of an FDA Black Box Warning detailing increased all-cause mortality in patients with non-life-threatening arrhythmias.[5] This pivotal finding has relegated quinidine to a niche but often indispensable therapeutic role. Today, it is recognized as a life-saving therapy for several rare, inherited channelopathies, including Brugada Syndrome and Short QT Syndrome, where its unique electrophysiological profile directly counteracts the underlying molecular pathology.[2]

In a modern example of pharmacological repurposing, a sub-therapeutic dose of quinidine is utilized as a potent inhibitor of the cytochrome P450 2D6 (CYP2D6) enzyme in a combination product with dextromethorphan (Nuedexta) for the treatment of Pseudobulbar Affect (PBA).[10] Despite its established efficacy in these specialized areas, quinidine faces a significant contemporary challenge: a pressing global crisis of limited availability. Economic and market forces have led to its discontinuation in many countries, creating a critical access problem for patients with rare syndromes who depend on this irreplaceable medication.[12] This report provides a comprehensive monograph on quinidine, detailing its chemical properties, historical context, complex pharmacology, evolving clinical applications, and extensive safety profile to serve as a definitive reference for clinicians and researchers.

2.0 Chemical Identity and Physicochemical Properties

A precise understanding of quinidine's chemical and physical nature is fundamental to appreciating its formulation, pharmacokinetics, and mechanism of action. This section delineates its nomenclature, structural characteristics, and key physicochemical properties.

2.1 Nomenclature and Identifiers

To ensure unambiguous identification across scientific and regulatory databases, quinidine is cataloged under a variety of systematic names and unique identifiers.

• Drug Name: Quinidine [1]
• Systematic (IUPAC) Name: (S)-octan-2-yl]-(6-methoxyquinolin-4-yl)methanol [2]
• CAS Number: 56-54-2.[1] A number of deprecated CAS numbers also exist and have been archived to prevent confusion in historical literature.[2]
• DrugBank ID: DB00908 [1]
• Synonyms: Quinidine is also known by several other names, including (+)-quinidine, (8R,9S)-Quinidine, Conquinine, Pitayine, and β-Quinine.[1]
• Other Key Identifiers:
• PubChem CID: 441074 [2]
• ChEBI ID: CHEBI:28593 [2]
• ChEMBL ID: CHEMBL1294 [2]
• FDA UNII: ITX08688JL [2]

2.2 Chemical Structure and Stereochemistry

Quinidine's molecular architecture and its specific three-dimensional arrangement are critical to its biological activity and its relationship with its famous stereoisomer, quinine.

• Chemical Formula: C20​H24​N2​O2​ [1]
• Molecular Weight: The average molecular weight is 324.4168 g/mol, with a monoisotopic mass of 324.183778022 Da.[1]
• Structural Description: Quinidine is a cinchona alkaloid, a class of natural products characterized by a core structure derived from the amino acid tryptophan. Its structure consists of a quinoline ring system linked via a hydroxymethyl bridge to a bicyclic quinuclidine ring system.[2] Specifically, it is defined as cinchonine in which the hydrogen at the 6-position of the quinoline ring is substituted by a methoxy group.[2]
• Stereoisomerism: The relationship between quinidine and quinine is a classic example of diastereomerism in pharmacology. Both molecules share the same chemical formula and atomic connectivity but differ in their spatial configuration at two of their four chiral centers: the carbon atom of the hydroxymethyl bridge (C9) and the carbon atom where the quinuclidine ring attaches to this bridge (C8).[2] Quinidine is the dextrorotatory stereoisomer, designated (8R,9S), while quinine is the levorotatory stereoisomer, designated (8S,9R).[1] Because they are stereoisomers but not mirror images (enantiomers) of each other, they are classified as diastereomers. This subtle yet profound difference in three-dimensional structure is responsible for their distinct pharmacological profiles. While both compounds possess antimalarial and sodium-channel-blocking properties, their interaction with cardiac potassium channels differs significantly. This stereochemical distinction is the primary reason why quinidine exhibits a much more pronounced effect on prolonging cardiac repolarization (and thus the QT interval) compared to quinine, making it the superior agent for treating certain repolarization-related channelopathies.[17]

2.3 Physical and Chemical Properties

The physical characteristics of quinidine influence its pharmaceutical formulation, stability, and behavior in biological systems.

• Appearance: Quinidine is a white to light-yellow crystalline powder. It is known to be triboluminescent and darkens upon exposure to light, indicating photosensitivity.[14]
• Solubility: As a free base, quinidine is practically insoluble in water, with a reported solubility of 0.05 g/100 mL at 20 °C.[14] However, it is soluble in organic solvents such as alcohol, methanol, and chloroform.[2] This poor aqueous solubility necessitates its formulation as various salts (e.g., sulfate, gluconate, hydrochloride) to improve dissolution and allow for oral and parenteral administration.[2]
• Melting Point: Sources report a melting point in the range of 168–174 °C.[2]
• Acidity/Basicity (pKa): Quinidine is a diacidic base, with two nitrogen atoms capable of being protonated. Its reported pKa values are approximately 5.4 and 10.0, with the stronger basic center (the quinuclidine nitrogen) having a pKa of around 9.05.[20] This means that at physiological pH (~7.4), quinidine will be predominantly in a protonated, charged state.
• Lipophilicity (LogP): The partition coefficient (LogP) is reported to be approximately 2.82, indicating moderate lipophilicity, which allows for good membrane permeability and a large volume of distribution.[21]
• Stability and Storage: Due to its light sensitivity, quinidine and its salt forms must be stored in well-closed, light-resistant containers.[14] It is typically stored in a dry environment, often under refrigeration at 2–8 °C, to ensure stability.[14]

The fundamental physicochemical properties of quinidine have directly shaped its journey as a pharmaceutical product. Its low water solubility drove the development of salt forms, which in turn enabled the creation of different formulations with distinct pharmacokinetic profiles, such as immediate-release sulfate tablets and extended-release gluconate tablets. Its sensitivity to light has dictated strict handling and storage protocols to prevent degradation and loss of potency. These properties are not merely academic details but are practical considerations that have influenced its clinical use for over a century.

Table 2.1: Physicochemical Properties of Quinidine

Property	Value	Source(s)
IUPAC Name	(S)-octan-2-yl]-(6-methoxyquinolin-4-yl)methanol	2
CAS Number	56-54-2	1
DrugBank ID	DB00908	1
Chemical Formula	C20​H24​N2​O2​	1
Average Molecular Weight	324.4168 g/mol	1
Monoisotopic Mass	324.183778022 Da	1
Appearance	White to light-yellow crystalline powder	17
Melting Point	168–174 °C	2
Water Solubility	0.05 g/100 mL (at 20 °C)	14
pKa	~5.4, ~10.0 (Strongest Basic: ~9.05)	20
LogP	2.82 (ALOGPS)	21
Storage Conditions	Store in a dark, dry place at 2–8 °C in light-resistant containers	14

3.0 Historical Development and Regulatory Landscape

The history of quinidine is a compelling narrative of serendipity, scientific inquiry, and the evolving standards of drug safety and efficacy. Its journey spans from a botanical remedy for fever to a revolutionary cardiac drug, followed by a period of decline due to safety concerns, and culminating in a modern renaissance as a precision therapy for rare diseases.

3.1 Discovery and Early Use as an Antimalarial

Quinidine's origins are inseparable from its botanical source, the Cinchona tree, native to the Andean forests of South America.[1] The bark of this tree, known as "Peruvian bark" or "quina-quina," was used by indigenous populations and later introduced to Europe by Jesuit missionaries in the 17th century as a remarkably effective treatment for fevers, particularly malaria.[22]

The active alkaloids were isolated in the 19th century. Quinidine was first isolated from Cinchona extracts and named by French chemists Henry and Delondre in 1833.[23] However, it was Louis Pasteur who, in 1853, definitively purified it and characterized it as a distinct dextrorotatory isomer of the more abundant levorotatory quinine.[23] In the latter half of the 19th century, quinidine saw extensive use as both an antimalarial and an antipyretic.[23] One of the earliest comparative clinical trials, conducted by the Madras Commission in India from 1866 to 1868, systematically evaluated the four principal Cinchona alkaloids. The results demonstrated that all four were effective against malaria, with quinidine showing a slightly lower failure rate than quinine.[23] Despite this evidence of comparable or superior efficacy, a shift in supply chains after 1890 to Javan Cinchona bark, which had a much higher natural abundance of quinine, led to quinine becoming the dominant global antimalarial agent for the next several decades.[23]

3.2 Emergence as the Prototypical Antiarrhythmic Agent

The discovery of quinidine's antiarrhythmic properties was a landmark event in cardiology. While French physician Jean-Baptiste de Sénac had alluded to the cardiac effects of cinchona bark as early as 1749, the modern application began with a remarkable clinical observation.[25] In 1912, the Dutch physician Karel Frederik Wenckebach was treating a merchant with persistent atrial fibrillation. The patient astutely reported that he could reliably terminate his own arrhythmia attacks by taking a gram of quinine.[4]

Intrigued by this report, other researchers began to investigate the Cinchona alkaloids more systematically. In 1918, Walter von Frey in Berlin published a seminal paper demonstrating that quinidine was the most effective of the four main alkaloids for controlling atrial arrhythmias.[1] This publication effectively launched the era of antiarrhythmic drug therapy, establishing quinidine as the first and prototypical Class IA agent. For decades, it was a cornerstone of treatment for atrial and ventricular arrhythmias. However, its prominence began to wane with the description of "quinidine syncope" in the 1950s—a phenomenon of sudden fainting spells later understood to be caused by the life-threatening arrhythmia Torsades de Pointes.[2] This significant safety concern, coupled with later meta-analyses that demonstrated an increased risk of mortality in patients treated for non-life-threatening arrhythmias, led to a dramatic decline in its use as newer, and presumably safer, agents and interventions like catheter ablation became available.[2]

3.3 Modern Regulatory Status and Clinical Renaissance

Despite its fall from widespread use, quinidine has retained its regulatory approval and has experienced a clinical renaissance in highly specific, niche indications.

• Regulatory Approval: In the United States, quinidine sulfate and quinidine gluconate formulations are approved by the Food and Drug Administration (FDA) for the management of life-threatening ventricular arrhythmias and for the treatment and prophylactic therapy of atrial fibrillation and flutter.[1] The intravenous formulation is also approved for treating life-threatening Plasmodium falciparum malaria.[6] Furthermore, a low-dose formulation of quinidine is a key component of the FDA-approved combination product Nuedexta, used for the treatment of Pseudobulbar Affect (PBA).[1]
• Global Status: The drug's regulatory status and availability are inconsistent globally. It was included in the very first WHO Model List of Essential Medicines in 1977 but has been removed from more recent editions.[32] In some countries, such as Canada, certain formulations have been discontinued.[33]
• Clinical Renaissance: The modern resurgence of interest in quinidine is driven by its unique efficacy in treating rare but life-threatening inherited channelopathies. Research has shown it to be a highly effective, and in some cases the only effective, oral therapy for preventing ventricular fibrillation in patients with Brugada Syndrome, Short QT Syndrome, and some forms of Idiopathic Ventricular Fibrillation.[2] In these specific contexts, where the risk of sudden cardiac death is high, the risk-benefit profile of quinidine shifts favorably, justifying its use despite its known toxicities.

3.4 Global Availability and Brand Formulations

The practical use of quinidine today is heavily constrained by challenges in its manufacturing and distribution.

• Brand Names and Formulations: Quinidine has been marketed under numerous brand names, including Cardioquin, Quinora, Quinidex, and Quinaglute.[17] Most of these brands have been discontinued, and the drug is now primarily available in its generic forms: quinidine sulfate (immediate and extended-release tablets) and quinidine gluconate (extended-release tablets).[35] The combination product with dextromethorphan is available as Nuedexta.[35]
• The Availability Crisis: The decline in its widespread use has made quinidine commercially unattractive for many pharmaceutical companies. This has led to a critical global availability crisis. A landmark 2013 survey of physicians in 131 countries found that quinidine was readily available in only 14% of nations. It was completely inaccessible in 76% of countries and available only through slow, restrictive regulatory processes in another 10%.[12] This lack of access has had dire consequences, with documented cases of patients with Brugada Syndrome suffering preventable arrhythmic events, including fatalities, because they could not obtain the drug.[12] The discontinuation of the intravenous formulation for the U.S. market in 2019 has further limited its utility in acute care settings.[4]

The history of quinidine serves as a powerful illustration of the life cycle of a drug, shaped by a dynamic interplay of efficacy, safety, and economics. Its initial rise was due to its revolutionary efficacy. Its decline was precipitated by a major safety signal. Its modern, niche role is a testament to its unique efficacy in specific diseases where the benefits clearly outweigh the risks. The final chapter of its story, however, is one of a potential public health failure, where a life-saving medication is becoming an "economic orphan," inaccessible to the very patients who need it most. This transition from a common medication to a de facto orphan drug highlights a systemic challenge in ensuring the continued availability of older, low-cost, but clinically indispensable medicines.

4.0 Pharmacology

The pharmacological profile of quinidine is exceptionally complex, characterized by effects on multiple ion channels and receptor systems. This complexity underpins its broad range of therapeutic actions as well as its significant potential for adverse effects and drug interactions.

4.1 Pharmacodynamics

Pharmacodynamically, quinidine's actions are defined by its effects on cardiac electrophysiology, its ancillary receptor activities, and its antimalarial mechanism.

4.1.1 Primary Antiarrhythmic Mechanism of Action (Class IA)

Quinidine is the archetypal Class IA antiarrhythmic agent in the Vaughan-Williams classification system.[17] Its primary antiarrhythmic effect stems from its ability to block the fast inward voltage-gated sodium channels (

INa​), which are responsible for the rapid phase 0 depolarization of the cardiac action potential. The specific channel isoform involved is Nav1.5, which is predominantly expressed in cardiac myocytes and Purkinje fibers.[1]

This channel blockade exhibits a property known as "use-dependence" or "state-dependence".[4] Quinidine has a higher affinity for sodium channels in their activated (open) and inactivated states than in their resting state. During a rapid heart rate (tachycardia), cardiac cells spend more time depolarized, meaning the sodium channels spend more time in the open and inactivated states. Consequently, the degree of channel blockade by quinidine intensifies at faster rates, making it particularly effective at interrupting tachyarrhythmias.[4] The functional consequence of this sodium channel blockade is a decrease in the maximum rate of rise of the action potential (Vmax), which translates to a slowing of electrical conduction velocity throughout all non-nodal cardiac tissues, including the atria, ventricles, and the His-Purkinje system.[6] This slowing of conduction is a key mechanism by which quinidine can interrupt and terminate arrhythmias that rely on a reentrant circuit.[1]

4.1.2 Effects on Cardiac Ion Channels (Na+, K+, Ca++)

Beyond its primary effect on the fast sodium current, quinidine's complex electrophysiological profile arises from its interaction with a wide array of other cardiac ion channels. This multi-channel blockade is what distinguishes Class IA agents and is responsible for both their unique therapeutic properties and their inherent risks.[1]

• Sodium Channels: In addition to blocking the peak fast inward sodium current (INa​), quinidine also inhibits the small, persistent late inward sodium current (late INa​).[1] Inhibition of this current can contribute to action potential shortening in the plateau phase but is a less dominant effect compared to its impact on peak INa​ and potassium currents.
• Potassium Channels: A hallmark of Class IA agents is the blockade of repolarizing potassium currents, which leads to a prolongation of the action potential duration. Quinidine is a non-selective potassium channel blocker, inhibiting multiple distinct currents:
• It blocks both the rapid (IKr​) and slow (IKs​) components of the delayed rectifier potassium current, which are crucial for phase 3 repolarization. The blockade of IKr​, which is mediated by the hERG channel, is the principal mechanism responsible for its significant QT-prolonging effect.[1]
• It inhibits the inward rectifier potassium current (IK1​), which helps maintain the resting membrane potential.[1]
• It blocks the transient outward potassium current (Ito​), which is responsible for the early, brief repolarization notch (phase 1) of the action potential. This specific action is of paramount importance for its therapeutic efficacy in Brugada Syndrome, as an overactive Ito​ current is a key pathophysiological mechanism in that disease.[1]
• Calcium Channels: Quinidine exerts a weak blocking effect on L-type calcium channels (ICa​).[1] This action contributes to the depression of the action potential plateau and is responsible for its negative inotropic (myocardial depressant) properties, which can be clinically relevant in patients with impaired ventricular function.[39]

4.1.3 Impact on the Cardiac Action Potential and Electrocardiogram (ECG)

The integrated effect of quinidine's multi-channel blockade produces characteristic and measurable changes in the cellular action potential and the surface electrocardiogram.

• Action Potential: Quinidine alters the morphology of the cardiac action potential in several ways. It decreases the amplitude and the maximum rate of rise (Vmax) of phase 0 depolarization. It also depresses the height of the plateau (phase 2) and, most critically, prolongs the overall duration of the action potential (APD) by slowing phase 3 repolarization.[15] This prolongation of the APD leads to a corresponding increase in the effective refractory period (ERP) of the cardiac tissue, making it less excitable and more resistant to premature stimuli.[39] The specific pattern of shortening the plateau while prolonging the final phase of repolarization can create conditions favorable for the development of early afterdepolarizations (EADs), which are the cellular triggers for Torsades de Pointes.[1]
• Electrocardiogram (ECG) Changes: These cellular effects are directly reflected on the surface ECG. Therapeutic concentrations of quinidine typically cause a widening of the QRS complex, which reflects the slowed intraventricular conduction velocity.[28] The most prominent and clinically monitored effect is a dose-related prolongation of the QT interval, which corresponds to the prolonged action potential duration.[1] The PR interval may also be prolonged due to slowed conduction through the atria and AV node.[39] Careful monitoring of the QRS duration and, especially, the QT interval is essential for guiding therapy and preventing toxicity.[6]

4.1.4 Ancillary Pharmacodynamic Effects

In addition to its direct effects on ion channels, quinidine possesses other pharmacological properties that influence its clinical profile and contribute to its side effects.

• Anticholinergic (Vagolytic) Activity: Quinidine has moderate activity as a muscarinic receptor antagonist.[2] This anticholinergic action blocks the effects of the vagus nerve on the heart, particularly at the sinoatrial (SA) and atrioventricular (AV) nodes.[1] This can lead to an increase in the sinus heart rate and, more critically, can enhance conduction through the AV node. This latter effect is the reason for the potential for a paradoxical increase in the ventricular response rate in patients with atrial flutter or fibrillation, necessitating prior rate control with an AV nodal blocking agent.[1]
• α-Adrenergic Blockade: Quinidine acts as a peripheral alpha-1 adrenergic receptor antagonist.[1] This action leads to vasodilation of peripheral blood vessels, which can result in a decrease in blood pressure and may cause hypotension, particularly when the drug is administered intravenously.[1]
• Negative Inotropy: Through its calcium channel blocking and direct myocardial depressant effects, quinidine reduces myocardial contractility.[1] This negative inotropic effect can be detrimental in patients with pre-existing systolic heart failure.[1]

The complex pharmacodynamic profile of quinidine is a quintessential "double-edged sword." The same molecular actions that provide its therapeutic benefits are also the direct cause of its most dangerous toxicities. The blockade of potassium channels is essential for prolonging the action potential to terminate re-entry, but it is this very action that prolongs the QT interval and creates the substrate for Torsades de Pointes. This is not a coincidental side effect but an intrinsic, inseparable extension of its core mechanism. This understanding is crucial for appreciating why the risk-benefit assessment for quinidine is so delicate and why its use is now restricted to clinical scenarios where the therapeutic gain is substantial enough to justify the inherent proarrhythmic risk.

4.1.5 Antimalarial Mechanism

As a stereoisomer of quinine, quinidine retains potent antimalarial activity. It functions primarily as an intra-erythrocytic schizonticide, targeting the parasite during the stage of its lifecycle within red blood cells.[1] The mechanism involves the drug accumulating in the acidic food vacuole of the

Plasmodium parasite. There, it is believed to interfere with the parasite's detoxification pathway, which involves polymerizing toxic heme (a byproduct of hemoglobin digestion) into an inert crystalline substance called hemozoin. By inhibiting this process, quinidine causes a buildup of cytotoxic free heme, which damages parasite membranes and leads to its death.[28] It is also gametocidal to

Plasmodium vivax and P. malariae, meaning it can kill the sexual forms of these parasites, but it is not effective against the gametocytes of the more virulent P. falciparum.[1]

4.2 Pharmacokinetics

The absorption, distribution, metabolism, and excretion (ADME) of quinidine are characterized by significant inter-patient variability and are influenced by numerous physiological factors and drug interactions.

4.2.1 Absorption and Bioavailability

Quinidine is generally well absorbed from the gastrointestinal tract following oral administration.[39] The absolute oral bioavailability is approximately 70% to 80%, with a notable range of 45% to 100% across individuals. This incomplete bioavailability is primarily due to first-pass metabolism in the liver.[1]

The rate of absorption depends on the salt form and formulation. Immediate-release quinidine sulfate tablets typically reach peak plasma concentrations (Tmax​) in about 2 hours.[28] In contrast, extended-release formulations, such as quinidine gluconate or extended-release quinidine sulfate, are absorbed more slowly, with a

Tmax​ of 3 to 6 hours.[1] Co-administration with food can delay the absorption of immediate-release forms but may enhance both the rate and extent of absorption of extended-release quinidine gluconate.[1] The ingestion of grapefruit juice has been reported to decrease the rate of absorption, in addition to its more significant metabolic interactions.[1]

4.2.2 Distribution and Protein Binding

Quinidine distributes extensively into body tissues, reflected by its large apparent volume of distribution (Vd), which is typically 2 to 3 L/kg in healthy young adults.[1] This Vd is highly sensitive to the patient's clinical state. It is significantly reduced in patients with congestive heart failure (to as low as 0.5 L/kg), which can lead to higher plasma concentrations for a given dose. Conversely, the Vd is increased in patients with liver cirrhosis (to 3 to 5 L/kg), which contributes to a longer elimination half-life in this population.[1]

Quinidine is highly bound to plasma proteins, with 80% to 88% of the drug bound in typical therapeutic concentrations.[1] The primary binding proteins are α1-acid glycoprotein (AAG) and, to a lesser extent, albumin.[1] This has important clinical implications, as AAG is an acute-phase reactant, meaning its levels increase in response to stress, such as an acute myocardial infarction. In such settings, the total measured quinidine concentration in the plasma may be markedly elevated due to increased binding, even while the concentration of the pharmacologically active, unbound (free) drug remains within the normal range.[28] Protein binding is lower in certain populations, such as pregnant women and neonates (as low as 50-70%).[1]

4.2.3 Metabolism: Cytochrome P450 Pathways and Active Metabolites

Metabolism is the primary route of elimination for quinidine, with 60% to 85% of a dose being cleared via biotransformation in the liver.[1]

• Metabolic Pathways: The principal metabolic pathway is hydroxylation, which is mediated predominantly by the cytochrome P450 3A4 (CYP3A4) isoenzyme.[1] This reliance on CYP3A4 makes quinidine a "victim" drug, susceptible to significant pharmacokinetic interactions with potent inhibitors and inducers of this enzyme.
• Active Metabolites: Quinidine is metabolized to several compounds, some of which retain pharmacological activity. The most important of these is 3-hydroxyquinidine (3HQ). This metabolite can reach plasma concentrations approaching those of the parent drug during chronic therapy and possesses at least half the antiarrhythmic activity of quinidine. Therefore, 3HQ is responsible for a substantial portion of the overall clinical effect observed with long-term quinidine use.[1] Other metabolites that have been identified include quinidine-N-oxide and quinidine 10,11-dihydrodiol.[1]
• Enzyme Inhibition: A defining pharmacokinetic feature of quinidine is its role as a potent inhibitor of another key drug-metabolizing enzyme, cytochrome P450 2D6 (CYP2D6).[1] This makes quinidine a significant "perpetrator" in drug-drug interactions. By inhibiting CYP2D6, therapeutic concentrations of quinidine can effectively convert individuals who are genetically extensive metabolizers of CYP2D6 substrates into functional poor metabolizers.[58] This property, while a source of numerous adverse drug interactions, has been ingeniously repurposed in the combination product Nuedexta. In this formulation, a low dose of quinidine is used specifically to inhibit the rapid CYP2D6-mediated metabolism of dextromethorphan, thereby boosting its central nervous system concentrations to therapeutic levels for the treatment of Pseudobulbar Affect. This represents a sophisticated clinical application of a drug's inhibitory pharmacokinetic properties.

4.2.4 Excretion and Elimination Half-Life

Quinidine is eliminated from the body through a combination of hepatic metabolism and renal excretion of the unchanged drug, with the latter accounting for 15% to 40% of total clearance.[1]

Renal clearance of quinidine is a complex process involving glomerular filtration, active tubular secretion, and pH-dependent tubular reabsorption.[1] The extent of renal excretion is highly dependent on urinary pH. In acidic urine (pH < 7), approximately 20% of an administered dose is excreted unchanged. However, in alkaline urine, the nonionized form of the drug predominates, leading to increased passive reabsorption from the renal tubules and a decrease in unchanged drug excretion to as little as 5%.[1] This makes its clearance susceptible to changes in diet or co-administration of urinary alkalinizing agents.

The elimination half-life (t1/2​) of quinidine in healthy adults is typically in the range of 6 to 8 hours.[1] The half-life is shorter in children (3 to 4 hours) and may be prolonged in elderly individuals and in patients with conditions that alter its pharmacokinetics, such as liver cirrhosis or congestive heart failure.[1]

The high degree of inter-patient variability in quinidine's pharmacokinetic profile, driven by factors such as organ function, age, genetics (CYP enzyme activity), and co-morbidities, underscores the necessity for individualized dosing. A standard dose can result in vastly different plasma concentrations and clinical effects from one patient to another. This reality necessitates careful clinical and ECG monitoring, and in many cases, therapeutic drug monitoring of plasma concentrations, to ensure both safety and efficacy.

5.0 Clinical Efficacy and Therapeutic Applications

The clinical utility of quinidine has evolved dramatically over time. Initially a mainstay for common arrhythmias, its role has been refined by a deeper understanding of its risk-benefit profile, leading to its current status as a specialized agent for specific, often life-threatening, conditions.

5.1 Management of Atrial Arrhythmias (Atrial Fibrillation and Flutter)

Historically, quinidine was the cornerstone of pharmacological therapy for atrial fibrillation (AF) and atrial flutter (AFl).[1] It was widely used for both the acute conversion of these arrhythmias to normal sinus rhythm, for which it is moderately efficacious, and for the long-term maintenance of sinus rhythm following successful cardioversion.[1]

However, its use in this common clinical setting has been largely abandoned. The primary reason for this shift was the compelling evidence from multiple meta-analyses demonstrating a significant increase in all-cause mortality in patients treated with quinidine for AF/AFl compared to placebo.[2] In the modern era, safer and often more effective alternatives, including other antiarrhythmic drugs and non-pharmacological interventions like catheter ablation, are preferred.[30] Consequently, quinidine is now considered a second- or third-line agent for AF/AFl, reserved for rare cases where other therapies have failed or are contraindicated.[30]

A critical clinical principle that remains relevant when quinidine is considered for AF/AFl is the absolute necessity of pre-treatment with an AV nodal blocking agent (e.g., a beta-blocker, non-dihydropyridine calcium channel blocker, or digoxin). Quinidine's anticholinergic (vagolytic) effect can enhance conduction through the AV node. If administered alone to a patient in atrial flutter, it can slow the atrial rate (e.g., from 300 to 220 beats per minute) while simultaneously improving AV conduction, which can lead to a paradoxical and hemodynamically catastrophic increase in the ventricular response rate (e.g., from 150 with 2:1 block to 220 with 1:1 block).[6]

5.2 Suppression of Life-Threatening Ventricular Arrhythmias

Quinidine is officially indicated for the suppression of recurrent, documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia (VT).[1] However, its application in this area is also limited by its significant proarrhythmic potential. The Cardiac Arrhythmia Suppression Trial (CAST), which studied other Class I antiarrhythmic agents, demonstrated that suppressing asymptomatic ventricular ectopy in post-myocardial infarction patients actually increased mortality. While quinidine was not in CAST, the "class effect" concern, combined with its own mortality data, has led to the recommendation that its use be avoided for less severe ventricular arrhythmias, such as asymptomatic premature ventricular contractions (PVCs).[6] For the acute treatment of PVCs, parenteral agents like lidocaine are generally preferred due to a better safety profile.[30]

5.3 Treatment of Inherited Channelopathies

The most important modern application of quinidine is in the management of rare, inherited cardiac channelopathies. In this context, it has transformed from a drug with a poor risk-benefit profile for common conditions to an indispensable, life-saving agent for specific genetic disorders. This represents a paradigm shift toward precision, mechanism-based therapy.

5.3.1 Brugada Syndrome (BrS)

Brugada Syndrome is a genetic disorder characterized by a distinctive ECG pattern of ST-segment elevation in the right precordial leads and an increased risk of sudden cardiac death from polymorphic VT or ventricular fibrillation (VF). The underlying pathophysiology involves an imbalance of ion currents that creates a transmural voltage gradient in the right ventricular epicardium, often due to an exaggerated transient outward potassium current (Ito​). Quinidine's remarkable efficacy in BrS is primarily attributed to its potent blockade of the Ito​ channel.[43] By inhibiting this current, quinidine helps to restore the action potential dome in the epicardium, reduce the transmural voltage gradient, normalize the ST-segment elevation on the ECG, and suppress the phase 2 re-entry mechanism that triggers lethal arrhythmias.[43]

Clinically, quinidine is used as an essential adjunctive therapy in BrS patients with an implantable cardioverter-defibrillator (ICD) who experience recurrent VF (arrhythmic storms) or frequent ICD shocks.[8] In some patient populations, particularly those who are not candidates for or refuse an ICD, long-term therapy guided by electrophysiology (EP) studies has been shown to be a safe and effective management strategy.[43]

5.3.2 Short QT Syndrome (SQTS)

Short QT Syndrome is another highly lethal genetic channelopathy characterized by an abnormally short QT interval on the ECG and a high risk of sudden cardiac death. The underlying cause is typically a gain-of-function mutation in genes encoding repolarizing potassium channels (e.g., KCNH2, which encodes the channel for the IKr​ current), leading to accelerated ventricular repolarization.[9]

Quinidine is the pharmacological treatment of choice for SQTS. Its mechanism is a direct countermeasure to the disease's pathophysiology. By blocking the overactive potassium channels (particularly IKr​), quinidine prolongs the action potential duration, normalizes the QT interval, and increases the effective refractory period, thereby preventing the induction of VT/VF.[7] Long-term treatment with quinidine (or its stereoisomer hydroquinidine) has been shown to be highly effective in prolonging the QTc interval and is associated with a dramatic reduction in life-threatening arrhythmic events in SQTS patients.[4]

5.3.3 Idiopathic Ventricular Fibrillation (IVF) and Early Repolarization Syndrome

Quinidine has also demonstrated efficacy in preventing recurrent arrhythmic events in patients diagnosed with Idiopathic Ventricular Fibrillation and in some patients with Early Repolarization Syndrome who have experienced malignant arrhythmias.[7] In these conditions, it is typically used as an adjunct to ICD therapy to reduce the burden of arrhythmias.

5.4 Combination Therapy for Pseudobulbar Affect (Dextromethorphan/Quinidine)

In an innovative example of drug repurposing, quinidine has found a novel application completely unrelated to its antiarrhythmic properties. A fixed-dose combination product containing 20 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate (Nuedexta) is FDA-approved for the treatment of Pseudobulbar Affect (PBA).[1] PBA is a neurological condition, often secondary to diseases like amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS), characterized by involuntary and uncontrollable episodes of laughing or crying that are incongruent with the patient's underlying emotional state.[11]

The therapeutic agent in this combination is dextromethorphan, which acts on sigma-1 and NMDA receptors in the central nervous system.[70] However, when administered alone, dextromethorphan is rapidly metabolized by the CYP2D6 enzyme, preventing it from reaching therapeutic concentrations. The role of the very low, sub-therapeutic dose of quinidine in this formulation is not to exert any direct effect of its own, but to act as a potent CYP2D6 inhibitor. By blocking the first-pass metabolism of dextromethorphan, quinidine increases its plasma concentrations by approximately 20-fold, effectively serving as a "pharmacokinetic booster" that allows dextromethorphan to become clinically effective.[4] Clinical trials have confirmed the efficacy of this combination in reducing the frequency of PBA episodes.[10] The combination has also been explored off-label for treating agitation in patients with dementia.[72]

5.5 Role in the Treatment of Severe Malaria

Quinidine retains an indication for the treatment of severe Plasmodium falciparum malaria, particularly in cases where the first-line agent, intravenous artesunate, is unavailable.[6] The CDC recommends a regimen of IV quinidine gluconate in conjunction with an oral antibiotic like doxycycline or clindamycin.[30]

While effective at clearing parasitemia, its use for malaria is fraught with challenges. The high doses required for antimalarial efficacy are associated with a significant risk of cardiovascular toxicity, most notably severe QT prolongation and Torsades de Pointes.[78] The increasing global availability of IV artesunate, which is recommended by the WHO as the drug of choice for severe malaria due to its superior safety profile and efficacy, has largely relegated quinidine to a secondary role.[30] Furthermore, the discontinuation of the intravenous formulation of quinidine in the United States complicates its use even in settings where it might be indicated.[4]

6.0 Safety and Tolerability Profile

The clinical use of quinidine is fundamentally constrained by its significant safety concerns, which range from common gastrointestinal intolerance to life-threatening cardiac events. A thorough understanding of its adverse effect profile and contraindications is paramount for its safe administration.

6.1 Black Box Warning: Increased Mortality Risk

The most critical safety issue associated with quinidine is encapsulated in a Black Box Warning issued by the U.S. Food and Drug Administration.[5] This warning is based on compelling evidence from multiple meta-analyses of randomized controlled trials.

• Core Warning: The analyses consistently showed that in patients with non-life-threatening arrhythmias, including both atrial fibrillation/flutter and ventricular premature contractions, treatment with quinidine was associated with a statistically significant increase in all-cause mortality compared to placebo or other antiarrhythmic drugs.[6] In the context of maintaining sinus rhythm in patients with atrial fibrillation, the relative risk of death was found to be more than threefold higher in the quinidine-treated groups compared to placebo.[6]
• Clinical Implication: This warning has profoundly reshaped the clinical application of quinidine. It establishes that the drug should not be used for arrhythmias that are not life-threatening, such as asymptomatic PVCs. Its use is now reserved for clinical scenarios where the arrhythmia itself poses a significant risk of mortality (e.g., sustained VT, Brugada Syndrome) and where the clinician judges that the potential benefits of treatment outweigh the substantial risk of increased death.[6] The risk is considered to be greatest in patients with underlying structural heart disease.[5]

6.2 Cardiovascular Adverse Events

The cardiovascular toxicity of quinidine is its most dangerous aspect and is directly related to its electrophysiological effects.

6.2.1 Proarrhythmia: QT Prolongation and Torsades de Pointes (TdP)

This is the most feared adverse event associated with quinidine.

• Mechanism: As a direct consequence of its therapeutic action of blocking the IKr​ potassium current, quinidine prolongs ventricular repolarization. This effect manifests on the ECG as a dose-dependent prolongation of the QT interval.[1] When the QT interval becomes excessively prolonged—particularly when the corrected QT interval (QTc) exceeds 500 milliseconds or increases by more than 60 ms from baseline—it creates an electrophysiological environment ripe for the development of early afterdepolarizations (EADs). These EADs can trigger a distinct, life-threatening polymorphic ventricular tachycardia known as Torsades de Pointes (TdP).[1]
• Clinical Presentation: TdP can be self-terminating, causing episodes of dizziness or syncope (famously termed "quinidine syncope"), or it can degenerate into ventricular fibrillation, leading to cardiac arrest and sudden death.[2]
• Risk Factors: While TdP can occur unpredictably, several factors are known to increase the risk. These include high plasma concentrations of quinidine, bradycardia, female gender, underlying structural heart disease, congenital long QT syndrome, and electrolyte disturbances, especially hypokalemia and hypomagnesemia.[1] Correction of electrolyte abnormalities is mandatory before and during therapy.

6.2.2 Other Cardiovascular Effects

• Hypotension: Can occur due to quinidine's peripheral α-adrenergic blocking properties, which cause vasodilation. The risk is highest with rapid intravenous infusion but can also occur with oral therapy.[39]
• Conduction Disturbances: A widening of the QRS complex is an expected pharmacological effect, but excessive widening (e.g., to more than 130% of the pre-treatment duration) is a sign of toxicity and requires dose reduction or discontinuation.[28] In patients with pre-existing conduction system disease, quinidine can precipitate high-degree atrioventricular (AV) block.[46]
• Heart Failure Exacerbation: Quinidine possesses negative inotropic properties, meaning it can depress myocardial contractility. This can lead to worsening of symptoms in patients with congestive heart failure.[1]
• Sinus Node Depression: In patients with sick sinus syndrome, quinidine's effects can lead to marked sinus node depression and severe bradycardia.[1]

6.3 Non-Cardiac Adverse Reactions

Quinidine is associated with a wide range of non-cardiac side effects, some of which are very common and can lead to discontinuation of therapy.

6.3.1 Cinchonism

This is a classic syndrome of dose-related toxicity caused by cinchona alkaloids.[39] It can occur with chronic use or even after a single dose in sensitive individuals. Symptoms include a characteristic constellation of neurological and gastrointestinal complaints: tinnitus (ringing in the ears), high-frequency hearing loss, vertigo, blurred or double vision, photophobia, headache, confusion, and delirium.[1] Nausea, vomiting, and diarrhea are also prominent features.[27]

6.3.2 Gastrointestinal Effects

Gastrointestinal intolerance is the most common reason for discontinuing quinidine therapy, affecting up to 30-35% of patients.[14] The primary symptoms are diarrhea, nausea, vomiting, anorexia, and abdominal pain or cramping.[39]

6.3.3 Hematologic and Immunologic Reactions

• Thrombocytopenia: Quinidine can cause a rare but potentially fatal immune-mediated thrombocytopenia. This occurs when a drug-dependent antibody forms, which binds to platelet surface glycoproteins only in the presence of quinidine, leading to rapid platelet destruction. The clinical presentation includes petechiae, bruising, or bleeding. This condition requires immediate and permanent discontinuation of the drug.[4] Because of cross-reactivity, patients with a history of quinidine- or quinine-induced thrombocytopenia should not receive either drug.[89]
• Other Reactions: Other rare but serious reactions include hemolytic anemia (which can be particularly severe in patients with G6PD deficiency), agranulocytosis, and a drug-induced lupus-like syndrome characterized by polyarthritis.[39]

6.3.4 Hepatic and Neurological Effects

• Hepatotoxicity: Quinidine has been associated with a hypersensitivity-type hepatitis, which can include granulomatous hepatitis. This typically occurs within the first few weeks of therapy, may present with fever, and generally resolves upon drug withdrawal.[4]
• Neurological: Common neurological side effects, often overlapping with cinchonism, include dizziness, light-headedness, headache, and fatigue.[39] Due to its anticholinergic properties, quinidine can exacerbate muscle weakness in patients with myasthenia gravis.[4]

6.4 Contraindications and Precautions

Given its narrow therapeutic index and significant risks, quinidine is contraindicated in several conditions.

• Absolute Contraindications:
• Known hypersensitivity to quinidine or other cinchona alkaloids.[39]
• A prior history of quinidine- or quinine-induced thrombocytopenic purpura.[46]
• Complete AV block or any cardiac rhythm that is dependent on a junctional or idioventricular escape pacemaker, unless the patient has a functioning artificial pacemaker.[46]
• Myasthenia gravis, due to the drug's anticholinergic effects.[4]
• Patients with congenital long QT syndrome or a history of Torsades de Pointes.[75]
• Precautions:
• Extreme caution is warranted in patients with pre-existing conduction system disease (e.g., second-degree AV block, bundle branch block), sick sinus syndrome, severe heart failure, or uncorrected electrolyte imbalances (hypokalemia, hypomagnesemia).[39]
• Dosage adjustments and careful monitoring are necessary in patients with significant hepatic or renal impairment due to altered drug clearance.[39]

Many of quinidine's adverse effects are not idiosyncratic but are predictable extensions of its complex pharmacology. The hypotension from α-blockade, the worsening of myasthenia gravis from anticholinergic effects, and the myocardial depression from negative inotropy are all direct consequences of its known receptor and channel interactions. This mechanistic understanding allows clinicians to anticipate specific risks based on a patient's comorbidities, rather than viewing side effects as random events. For instance, a patient with borderline hypotension, underlying myasthenia gravis, or severe systolic dysfunction would be an exceptionally poor candidate for quinidine therapy.

7.0 Drug and Food Interactions

Quinidine is involved in a vast number of clinically significant drug and food interactions due to its complex pharmacodynamic and pharmacokinetic profiles. It acts as both a "victim" of interactions that alter its metabolism and a "perpetrator" that alters the metabolism of other drugs. Safe use of quinidine requires a thorough review of a patient's concomitant medications.

7.1 Pharmacodynamic Interactions

These interactions occur when co-administered drugs have additive or synergistic effects at the site of action, primarily the heart.

• Additive QT Prolongation: This is the most critical and potentially lethal pharmacodynamic interaction. When quinidine is given with other medications that also prolong the QT interval, the risk of Torsades de Pointes increases synergistically. This list of interacting drugs is extensive and includes:
• Antiarrhythmics: Class IA (e.g., procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, dofetilide) agents.[27]
• Antipsychotics: Phenothiazines (e.g., thioridazine, chlorpromazine) and atypical agents (e.g., ziprasidone, haloperidol).[36]
• Antibiotics: Macrolides (e.g., clarithromycin, azithromycin) and fluoroquinolones (e.g., moxifloxacin, levofloxacin).[36]
• Other Agents: Tricyclic antidepressants (e.g., amitriptyline), certain antifungals, and antiemetics (e.g., ondansetron).[36]
• The combination with drugs that both prolong the QT interval and are metabolized by CYP2D6 (e.g., thioridazine) is explicitly contraindicated because quinidine's inhibition of their metabolism further amplifies the risk.[31]
• Enhanced Anticoagulant Effect: Quinidine can potentiate the anticoagulant effect of warfarin, increasing the risk of hypoprothrombinemic hemorrhage. The mechanism is not fully understood, but close monitoring of the International Normalized Ratio (INR) is essential when these drugs are used together.[39]
• Potentiation of Neuromuscular Blockade: Quinidine can enhance the effects of both depolarizing (e.g., succinylcholine) and non-depolarizing (e.g., pancuronium, d-tubocurarine) neuromuscular blocking agents. This can lead to prolonged muscle weakness and respiratory depression post-surgery.[39]

7.2 Pharmacokinetic Interactions

Quinidine's involvement with the cytochrome P450 enzyme system and the P-glycoprotein transporter makes it a central figure in numerous pharmacokinetic interactions.

7.2.1 Quinidine as a Potent CYP2D6 Inhibitor

Quinidine is one of the most potent known inhibitors of the CYP2D6 enzyme.[4] This makes it a significant "perpetrator" of drug interactions. It can dramatically increase the plasma concentrations and potential toxicity of numerous drugs that are metabolized by this pathway. Important CYP2D6 substrates include:

• Beta-blockers: Metoprolol, propranolol, timolol.
• Antidepressants: Tricyclic antidepressants (e.g., desipramine, nortriptyline) and SSRIs (e.g., paroxetine, fluoxetine).
• Opioids: Codeine, hydrocodone, oxycodone (quinidine can block the conversion of codeine to its active metabolite, morphine, reducing its analgesic effect).
• Other Antiarrhythmics: Propafenone, flecainide.[4]

7.2.2 Interactions Affecting Quinidine Metabolism (as a CYP3A4 Substrate)

Quinidine is a "victim" of drugs that modulate the CYP3A4 enzyme, its primary metabolic pathway.[1]

• CYP3A4 Inhibitors: Co-administration with strong CYP3A4 inhibitors can decrease quinidine's metabolism, leading to elevated plasma levels and an increased risk of toxicity (especially TdP). Potent inhibitors include:
• Azole antifungals (ketoconazole, itraconazole)
• HIV protease inhibitors (ritonavir)
• Macrolide antibiotics (clarithromycin)
• Amiodarone and cimetidine also inhibit its metabolism.[27]
• CYP3A4 Inducers: Co-administration with strong CYP3A4 inducers can accelerate quinidine's metabolism, resulting in lower plasma concentrations and a potential loss of antiarrhythmic efficacy. Potent inducers include:
• Rifampin
• Anticonvulsants (phenobarbital, phenytoin, carbamazepine).[39]

7.2.3 P-glycoprotein (P-gp)-Mediated Interactions

Quinidine is a potent inhibitor of the P-glycoprotein (P-gp) efflux transporter.[4]

• Digoxin Interaction: This is a classic, clinically critical interaction. Digoxin is a substrate of P-gp in the renal tubules and other tissues. By inhibiting P-gp, quinidine reduces the renal clearance of digoxin and also decreases its apparent volume of distribution. The net result can be a doubling of steady-state digoxin serum concentrations, which significantly increases the risk of digitalis toxicity. Standard practice requires reducing the digoxin dose by approximately 50% when initiating quinidine therapy, followed by close monitoring of digoxin levels.[14]

7.2.4 Interactions Affecting Renal Excretion

• Urinary Alkalinizers: Drugs that increase urinary pH, such as sodium bicarbonate, carbonic anhydrase inhibitors (e.g., acetazolamide), and thiazide diuretics, decrease the renal excretion of quinidine. By making the urine more alkaline, they increase the proportion of nonionized quinidine in the renal tubules, which enhances its passive reabsorption back into the bloodstream. This can lead to elevated quinidine levels and toxicity.[1]

7.3 Food Interactions

• Grapefruit Juice: This is a well-documented and clinically significant food-drug interaction. Grapefruit juice contains furanocoumarins, which are potent, mechanism-based inhibitors of intestinal CYP3A4.[93] By inhibiting this enzyme in the gut wall, grapefruit juice reduces the first-pass metabolism of quinidine, leading to increased oral bioavailability and higher systemic concentrations, which can precipitate toxicity.[58] Because this inhibition is irreversible and requires de novo synthesis of the enzyme, its effects can last for up to 72 hours, and simply separating the timing of drug and juice intake is not effective.[95] Patients taking quinidine should be counseled to avoid grapefruit and grapefruit juice completely.[84]
• Dietary Salt: Alterations in dietary salt intake can influence quinidine levels. Patients are advised to maintain a consistent daily salt intake to avoid fluctuations in drug concentrations.[84]

Table 7.1: Clinically Significant Drug Interactions with Quinidine

Interacting Agent/Class	Mechanism of Interaction	Potential Clinical Effect	Management Recommendation
Pharmacodynamic Interactions
Amiodarone, Sotalol, Dofetilide, Procainamide, Antipsychotics, Macrolides, Fluoroquinolones	Additive QT prolongation	Increased risk of Torsades de Pointes, syncope, sudden death	Avoid combination if possible. If unavoidable, requires intensive ECG monitoring. Some combinations are contraindicated.
Warfarin	Potentiation of anticoagulant effect (mechanism unclear)	Increased INR, risk of hemorrhage	Monitor INR closely upon initiation, dose adjustment, or discontinuation of quinidine.
Neuromuscular Blockers (e.g., Succinylcholine, Pancuronium)	Potentiation of neuromuscular blockade	Prolonged muscle weakness, respiratory depression	Use with caution, especially in the perioperative setting. Monitor respiratory function.
Pharmacokinetic Interactions
Digoxin	P-glycoprotein inhibition by quinidine	Doubling of serum digoxin levels, increased risk of digitalis toxicity	Reduce digoxin dose by ~50% when starting quinidine. Monitor serum digoxin levels and for signs of toxicity.
Metoprolol, Codeine, Tricyclic Antidepressants	CYP2D6 inhibition by quinidine	Increased plasma levels of the substrate drug, leading to increased effects or toxicity (e.g., bradycardia with metoprolol)	Monitor for adverse effects of the substrate drug. Dose reduction of the substrate may be necessary.
Ketoconazole, Ritonavir, Clarithromycin (CYP3A4 Inhibitors)	Inhibition of quinidine metabolism	Increased quinidine levels, increased risk of QT prolongation and TdP	Avoid combination if possible. If necessary, consider a lower quinidine dose and monitor ECG and quinidine levels closely.
Rifampin, Phenytoin, Phenobarbital (CYP3A4 Inducers)	Induction of quinidine metabolism	Decreased quinidine levels, potential loss of antiarrhythmic efficacy	Avoid combination. If necessary, monitor quinidine levels and clinical response; a higher quinidine dose may be required.
Sodium Bicarbonate, Thiazide Diuretics (Urinary Alkalinizers)	Decreased renal excretion of quinidine	Increased quinidine levels and risk of toxicity	Monitor for signs of quinidine toxicity. Avoid excessive use of antacids containing sodium bicarbonate.
Grapefruit Juice	Inhibition of intestinal CYP3A4	Increased oral bioavailability and plasma levels of quinidine, risk of toxicity	Counsel patient to completely avoid grapefruit and grapefruit juice during therapy.

8.0 Dosing, Administration, and Special Populations

The safe and effective use of quinidine requires careful attention to its various formulations, specific dosing regimens tailored to the indication, and necessary adjustments for special patient populations. Its narrow therapeutic window necessitates individualized therapy and close monitoring.

8.1 Formulations and Dosing Regimens

Quinidine is commercially available as two different salts, quinidine sulfate and quinidine gluconate. It is critically important to recognize that these salt forms are not bioequivalent on a milligram-for-milligram basis because they contain different proportions of the active quinidine base. Failure to account for this difference is a potential source of significant medication error.

• Formulations:
• Quinidine Sulfate: Typically available as immediate-release tablets (200 mg and 300 mg) and extended-release tablets (300 mg). 200 mg of quinidine sulfate contains 166 mg of active quinidine base.[28]
• Quinidine Gluconate: Available as extended-release tablets (324 mg). 324 mg of quinidine gluconate contains 202 mg of active quinidine base. Thus, on a molar basis, approximately 267 mg of quinidine gluconate is equivalent to 200 mg of quinidine sulfate.[28] An injectable formulation for intravenous use was historically available but has been discontinued in the United States, limiting its use in acute settings.[4]
• Administration:
• Oral tablets may be administered with food to reduce gastrointestinal side effects.[30]
• Extended-release tablets should be swallowed whole and not chewed or crushed to maintain their controlled-release properties. Some quinidine gluconate tablets are scored and may be split in half.[30]
• A test dose of 200 mg of quinidine sulfate is often recommended several hours before initiating a full therapeutic regimen to screen for idiosyncratic hypersensitivity reactions.[30]
• Therapeutic Monitoring: Due to high inter-patient variability, therapy must be individualized. Monitoring should include clinical assessment of arrhythmia control, regular ECGs to assess QRS duration and the QT interval, and, when indicated, measurement of plasma quinidine concentrations. The generally accepted therapeutic range is 2 to 6 mg/L (or mcg/mL).[39] The dose should be reduced or the drug discontinued if signs of toxicity appear, such as the QRS complex widening to >130% of its baseline, the QTc interval exceeding 500 ms, the disappearance of P waves, or the development of significant hypotension or bradycardia.[28]

Table 8.1: Dosing Regimens for Quinidine by Indication

Indication	Formulation	Adult Dosage	Pediatric Dosage	Key Monitoring Parameters
Atrial Fibrillation/Flutter	Quinidine Sulfate (Immediate-Release)	Conversion: 300-400 mg PO every 6 hours. Maintenance: 200-400 mg PO every 6-8 hours.	30 mg/kg/day PO in 5 divided doses.	ECG (QTc, QRS), heart rate, blood pressure. Ensure prior AV nodal blockade.
	Quinidine Gluconate (Extended-Release)	Conversion: 648 mg PO every 8 hours for 3-4 doses. Maintenance: 324-648 mg PO every 8-12 hours.	Not generally recommended.	ECG (QTc, QRS), heart rate, blood pressure. Ensure prior AV nodal blockade.
Life-Threatening Ventricular Arrhythmias	Quinidine Sulfate (Immediate-Release)	200-400 mg PO every 6-8 hours.	15-60 mg/kg/day PO divided every 6 hours.	ECG (QTc, QRS), plasma levels, Holter monitoring, assessment of arrhythmia burden.
	Quinidine Gluconate (Extended-Release)	324-660 mg PO every 8-12 hours.	Not generally recommended.	ECG (QTc, QRS), plasma levels, Holter monitoring, assessment of arrhythmia burden.
Severe Malaria (P. falciparum)	Quinidine Gluconate (IV) (Availability is limited)	Loading Dose: 10 mg/kg IV over 1-2 hours. Maintenance: 0.02 mg/kg/min continuous IV infusion. (Administer with doxycycline or clindamycin).	Same as adult dose.	Continuous ECG monitoring, blood pressure, blood glucose, parasitemia levels.
Pseudobulbar Affect (PBA)	Dextromethorphan/ Quinidine Sulfate (Oral Capsule)	One capsule (20 mg/10 mg) PO once daily for 7 days, then increase to one capsule every 12 hours.	Use and dose not established.	ECG at baseline, particularly in patients with cardiac risk factors.

8.2 Use in Pediatric and Geriatric Populations

• Pediatric Use: Quinidine has been used in children for both arrhythmias and malaria, although its use is not widespread and often occurs in specialized settings.[76] Pharmacokinetic studies show that children may clear quinidine two to three times more rapidly than adults, with a correspondingly shorter elimination half-life of 3 to 4 hours.[1] Dosing is therefore typically weight-based, with a common regimen for arrhythmias being 15-60 mg/kg/day of quinidine sulfate divided into doses every 6 hours.[36] Extended-release formulations are generally not recommended due to a lack of data in this population.[77]
• Geriatric Use: While quinidine is not contraindicated based on age alone, elderly patients often exhibit reduced clearance and a prolonged elimination half-life.[53] This can lead to drug accumulation and an increased risk of adverse effects, particularly proarrhythmia and CNS toxicity. Therefore, lower initial doses and more cautious titration are generally recommended in the elderly.[76] Furthermore, geriatric patients are more likely to have co-morbidities such as structural heart disease, renal or hepatic impairment, and polypharmacy, all of which increase the risk associated with quinidine therapy.

8.3 Use in Pregnancy and Lactation

• Pregnancy: Quinidine is classified as FDA Pregnancy Category C, indicating that animal reproduction studies have not been conducted and there are no adequate and well-controlled studies in humans.[106] The drug is known to cross the placenta.[106] Despite the lack of formal studies, there is a history of its use for treating both maternal and fetal tachyarrhythmias, as well as for managing acute malaria in pregnant women. Retrospective data have not shown a clear association with major congenital abnormalities, but a rare case of neonatal thrombocytopenia has been reported following maternal ingestion.[106] The decision to use quinidine during pregnancy requires a careful weighing of the potential benefits to the mother against the potential risks to the fetus.[5]
• Lactation: Quinidine is excreted into human breast milk, with milk concentrations typically being slightly lower than those in the maternal serum.[106] The available data, though limited, suggest that maternal doses up to 1.8 grams daily result in low levels in the milk and are not expected to cause adverse effects in a breastfed infant, particularly if the infant is older than 2 months. Nevertheless, the manufacturer recommends that a decision be made to either discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. If used, careful monitoring of the infant for any adverse effects is advised.[106]

8.4 Dosing Adjustments in Renal and Hepatic Impairment

• Hepatic Impairment: As quinidine is extensively metabolized by the liver via the CYP3A4 pathway, its clearance is significantly impaired in patients with hepatic dysfunction, especially cirrhosis. This leads to a prolonged half-life and an increased risk of accumulation and toxicity.[53] A dose reduction is recommended for these patients, although specific, validated guidelines are lacking. Therapy must be initiated with caution and guided by close clinical and ECG monitoring.[28]
• Renal Impairment: The need for dose adjustment in renal impairment is less clear. While 15-40% of the drug is cleared by the kidneys, this pathway is less dominant than hepatic metabolism. Most sources suggest that no dose adjustment is necessary for mild to moderate renal impairment.[103] For patients with severe renal impairment (e.g., Creatinine Clearance [CrCl] < 10 mL/min), some guidelines recommend reducing the dose to 75% of normal.[36] Given the conflicting information and the potential for accumulation of both parent drug and metabolites, cautious use and monitoring are prudent in patients with severe renal disease.

The dosing recommendations for special populations are largely derived from an understanding of the drug's pharmacokinetic principles rather than from large, robust clinical trials. For example, the recommendation for lower doses in the elderly is based on the knowledge of age-related decline in drug clearance, not on specific geriatric trials. This reflects the age of the drug and highlights a significant evidence gap. Consequently, clinical judgment, cautious dose titration, and vigilant monitoring for efficacy and toxicity are paramount when using quinidine outside of the standard adult population.

9.0 Conclusion and Future Perspectives

Quinidine occupies a paradoxical and precarious position in the modern pharmacopeia. Its history charts a dramatic trajectory from a widely used, revolutionary antiarrhythmic to a drug largely abandoned for common conditions due to a significant mortality risk. Yet, this decline has been paralleled by a renaissance, as its unique electrophysiological properties have proven to be indispensable for managing some of the rarest and most lethal inherited cardiac channelopathies.

The synthesis of available data confirms that quinidine is a drug of profound dualities. Its multi-channel blockade, the very source of its efficacy in terminating arrhythmias, is also the direct cause of its most dangerous proarrhythmic toxicity, Torsades de Pointes. Its complex pharmacokinetic profile, involving major cytochrome P450 pathways, makes it both a victim and a perpetrator of numerous drug interactions, demanding a high level of pharmacological vigilance from clinicians. This same inhibitory property, however, has been ingeniously repurposed in a combination product to enable the therapeutic effect of another drug, showcasing remarkable pharmacological innovation.

While newer agents and technologies have rightly superseded quinidine for the treatment of common arrhythmias like atrial fibrillation, no other available oral medication has been shown to replicate its specific and life-saving efficacy in Brugada Syndrome and Short QT Syndrome. For patients with these conditions, quinidine is not merely an alternative; it is often the only effective pharmacological therapy capable of preventing sudden cardiac death.

This reality brings the most pressing contemporary issue into sharp focus: the growing crisis of its global availability. As a low-cost, off-patent drug with a narrow set of modern indications, quinidine has become commercially unviable for many manufacturers. The result is a worldwide patchwork of inconsistent access, where a life-saving medication is often unavailable to the very patients who need it most. This situation poses a significant public health challenge and raises broader questions about the sustainability of essential medicines in the modern pharmaceutical market. It underscores a critical need for new models of stewardship, involving regulatory agencies, patient advocacy groups, and pharmaceutical companies, to ensure that older, inexpensive, but clinically essential drugs like quinidine remain available.

Looking forward, while large-scale clinical trials with quinidine are unlikely, further research into its complex interactions with specific ion channel mutations may continue to yield valuable insights into the fundamental mechanisms of cardiac electrophysiology and arrhythmogenesis. The legacy of quinidine is thus a powerful reminder that a drug's value is not static; it evolves with our understanding of disease, and its continued existence can depend as much on economic and logistical factors as it does on its proven clinical merit.

Works cited

1. Quinidine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 4, 2025, https://go.drugbank.com/drugs/DB00908
2. Quinidine | C20H24N2O2 | CID 441074 - PubChem, accessed September 4, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Quinidine
3. go.drugbank.com, accessed September 4, 2025, https://go.drugbank.com/drugs/DB00908#:~:text=The%20antiarrhythmic%20actions%20of%20this,depolarization%20of%20the%20action%20potential.
4. Quinidine - Wikipedia, accessed September 4, 2025, https://en.wikipedia.org/wiki/Quinidine
5. Quinidine | Side Effects, Dosage, Uses, and More - Healthline, accessed September 4, 2025, https://www.healthline.com/health/drugs/quinidine-oral-tablet
6. 1081 QUINIDINE_GLUCONATE_8_09.ps - 9/21/2009 2:07 PM, accessed September 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/089338s036lbl.pdf
7. Quinidine gluconate | DrugBank Online, accessed September 4, 2025, https://go.drugbank.com/salts/DBSALT001251
8. Quinidine effective for the management of ventricular and, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6050440/
9. Further Insights into the Effect of Quinidine in Short QT Syndrome, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1474841/
10. Quinidine Completed Phase 3 Trials for Pseudobulbar Affect (PBA) Treatment - DrugBank, accessed September 4, 2025, https://go.drugbank.com/drugs/DB00908/clinical_trials?conditions=DBCOND0038672&phase=3&purpose=treatment&status=completed
11. Dextromethorphan and Quinidine: MedlinePlus Drug Information, accessed September 4, 2025, https://medlineplus.gov/druginfo/meds/a611048.html
12. Quinidine, A Life-Saving Medication for Brugada Syndrome, Is Inaccessible in Many Countries - JACC Journals, accessed September 4, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2013.02.077
13. Quinidine - CAS Common Chemistry, accessed September 4, 2025, https://commonchemistry.cas.org/detail?cas_rn=56-54-2&search=56-54-2
14. CAS 56-54-2 Quinidine - Alfa Chemistry, accessed September 4, 2025, https://www.alfa-chemistry.com/product/quinidine-cas-56-54-2-180968.html
15. Quinidine (CAS 56-54-2) - Cayman Chemical, accessed September 4, 2025, https://www.caymanchem.com/product/20356/quinidine
16. Quinidine 0611, CAS 56-54-2 - Quinoline - Extrasynthese, accessed September 4, 2025, https://www.extrasynthese.com/quinoline/868-quinidine.html
17. 56-54-2 | CAS DataBase - ChemicalBook, accessed September 4, 2025, https://m.chemicalbook.com/CASEN_56-54-2.htm
18. Quinine | C20H24N2O2 | CID 3034034 - PubChem, accessed September 4, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Quinine
19. Antiarrhythmic Activity of Quinine in Humans - American Heart Association Journals, accessed September 4, 2025, https://www.ahajournals.org/doi/10.1161/01.cir.92.10.2944
20. Quinidine | 56-54-2 - ChemicalBook, accessed September 4, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9208047.htm
21. Quinidine sulfate | DrugBank Online, accessed September 4, 2025, https://go.drugbank.com/salts/DBSALT000363
22. A historical look at 5 popular heart medications: Are you taking any of them? | What's Up at Upstate, accessed September 4, 2025, https://www.upstate.edu/whatsup/2019/0503-a-historical-look-at-5-popular-heart-medications-are-you-taking-any-of-them.php
23. Full article: Widened Scope of Drug Repurposing/Chiral Switches, Elements of Secondary Pharmaceuticals: The Quinine/Quinidine Case - Taylor & Francis Online, accessed September 4, 2025, https://www.tandfonline.com/doi/full/10.4155/fdd-2023-0006
24. Historical Review: Problematic Malaria Prophylaxis with Quinine - PMC, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4973170/
25. Quinidine sulphate - RACGP, accessed September 4, 2025, https://www.racgp.org.au/the-racgp/history/the-racgp-museum-collection/medicines-and-therapeutics/quinidine-sulphate
26. History of use of anti-arrhythmic agents [OzEMedicine - Wiki for Australian Emergency Medicine Doctors], accessed September 4, 2025, https://www.ozemedicine.com/wiki/doku.php?id=hantiarrhythmics
27. Quinidex (Quinidine): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 4, 2025, https://www.rxlist.com/quinidex-drug.htm
28. Quinidine - StatPearls - NCBI Bookshelf, accessed September 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK542193/
29. QUINIDINE SULFATE - FDA Approval - MedPath, accessed September 4, 2025, https://trial.medpath.com/drug/approvals/fda/ec2509eb234ced4c
30. QuiNIDine Monograph for Professionals - Drugs.com, accessed September 4, 2025, https://www.drugs.com/monograph/quinidine.html
31. NUEDEXTA (dextromethorphan hydrobromide and quinidien sulfate) - accessdata.fda.gov, accessed September 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf
32. Widened Scope of Drug Repurposing/Chiral Switches, Elements of Secondary Pharmaceuticals: The Quinine/Quinidine Case - Taylor & Francis Online, accessed September 4, 2025, https://www.tandfonline.com/doi/pdf/10.4155/fdd-2023-0006
33. Product information - Canada.ca, accessed September 4, 2025, https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1038
34. Quinidine-A legacy within the modern era of antiarrhythmic therapy - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/31026503/
35. Quinidine - brand name list from Drugs.com, accessed September 4, 2025, https://www.drugs.com/ingredient/quinidine.html
36. Quinaglute, Quinidex (quinidine) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed September 4, 2025, https://reference.medscape.com/drug/quinaglute-quinidex-quinidine-342308
37. Quinidine: Uses, Side Effects, Dosage & Reviews - GoodRx, accessed September 4, 2025, https://www.goodrx.com/quinidine/what-is
38. Quinidine gluconate - KEGG DRUG, accessed September 4, 2025, https://www.genome.jp/dbget-bin/www_bget?D00642
39. quinidine gluconate, accessed September 4, 2025, https://www.glowm.com/resources/glowm/cd/pages/drugs/qr002.html
40. Class I Antiarrhythmics (Sodium-Channel Blockers) - CV Pharmacology, accessed September 4, 2025, https://cvpharmacology.com/antiarrhy/sodium-blockers
41. Quinidine blocks cardiac sodium channels during opening and slow inactivation in guinea-pig papillary muscle - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/2451964/
42. What is the mechanism of Quinidine Sulfate? - Patsnap Synapse, accessed September 4, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-quinidine-sulfate
43. Quinidine in Brugada Syndrome | Cardiolatina, accessed September 4, 2025, http://cardiolatina.com/wp-content/uploads/2020/03/Quinidine-in-Brugada-Syndrome-.pdf
44. Pharmacological Therapy in Brugada Syndrome - Arrhythmia and Electrophysiology Review, accessed September 4, 2025, https://www.aerjournal.com/articles/pharmacological-therapy-brugada-syndrome?language_content_entity=en
45. Effects of quinidine on action potentials and ionic currents in isolated canine ventricular myocytes - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/2448058/
46. Quinidine: Package Insert / Prescribing Information - Drugs.com, accessed September 4, 2025, https://www.drugs.com/pro/quinidine.html
47. www.ahajournals.org, accessed September 4, 2025, https://www.ahajournals.org/doi/pdf/10.1161/01.RES.62.2.324#:~:text=Quinidine%20also%20reduced%20plateau%20height,of%20the%20control%20action%20potential.
48. Effects of quinidine on action potentials and ionic currents in isolated canine ventricular myocytes. - American Heart Association Journals, accessed September 4, 2025, https://www.ahajournals.org/doi/pdf/10.1161/01.RES.62.2.324
49. Drugs affecting cardiac rhythm - Johns Hopkins University, accessed September 4, 2025, https://pure.johnshopkins.edu/en/publications/drugs-affecting-cardiac-rhythm
50. CHEBI:28593 - quinidine - EMBL-EBI, accessed September 4, 2025, https://www.ebi.ac.uk/chebi/chebiOntology.do?chebiId=CHEBI:28593
51. Pharmacokinetic studies of quinidine in patients with arrhythmias. - AHA Journals, accessed September 4, 2025, https://www.ahajournals.org/doi/abs/10.1161/circ.55.1.1/b
52. Absolute quinidine bioavailability - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/954347/
53. Clinical pharmacokinetics of quinidine - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/6988137/
54. Quinidine - Basicmedical Key, accessed September 4, 2025, https://basicmedicalkey.com/quinidine/
55. Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network - PMC, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10431052/
56. quinidine - PharmGKB, accessed September 4, 2025, https://www.pharmgkb.org/chemical/PA451209
57. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/16162505/
58. Drugs@FDA: Drug Product Quinidine Gluconate (Quinidine Gluconate), ANDA089338, Carilion Materials Management - ClinPGx, accessed September 4, 2025, https://www.clinpgx.org/literature/15102013
59. Annotation of FDA Label for quinidine and CYP2D6 - ClinPGx, accessed September 4, 2025, https://www.clinpgx.org/labelAnnotation/PA166104811
60. Pharmacology of Antiarrhythmics: Quinidine, Beta-Blockers, Diphenylhydantoin, Bretylium * - VCU Scholars Compass, accessed September 4, 2025, https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=1721&context=mcvq
61. Chapter 9. Quinidine | Applied Clinical Pharmacokinetics, 2e - AccessPharmacy, accessed September 4, 2025, https://accesspharmacy.mhmedical.com/content.aspx?bookid=510§ionid=40843095
62. Quinidine for Brugada syndrome: Panacea or poison? - PMC, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5419994/
63. Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome - JACC Journals, accessed September 4, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2017.10.025
64. pmc.ncbi.nlm.nih.gov, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1474841/#:~:text=Oral%20quinidine%20is%20effective%20in,ventricular%20tachycardia%2Fventricular%20fibrillation%20noninducible.
65. A historical outline of quinidine - Medigraphic, accessed September 4, 2025, https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=56595
66. Abstract 23071: Hydroquinidine Abolishes Life-threatening Arrhythmic Events in Patients With Short QT Syndrome | Circulation - American Heart Association Journals, accessed September 4, 2025, https://www.ahajournals.org/doi/10.1161/circ.136.suppl_1.23071
67. Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/29241489/
68. Dextromethorphan and quinidine (oral route) - Side effects & dosage - Mayo Clinic, accessed September 4, 2025, https://www.mayoclinic.org/drugs-supplements/dextromethorphan-and-quinidine-oral-route/description/drg-20074618
69. Nuedexta for the Treatment Of Pseudobulbar Affect: A Condition of Involuntary Crying or Laughing - PMC - PubMed Central, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3737988/
70. Dextromethorphan-quinidine–responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression? | CNS Spectrums | Cambridge Core, accessed September 4, 2025, https://www.cambridge.org/core/journals/cns-spectrums/article/dextromethorphanquinidineresponsive-pseudobulbar-affect-pba-psychopharmacological-model-for-wideranging-disorders-of-emotional-expression/405FE13AB680859DDBCF3E15E00E29B0
71. Is dextromethorphan effective in treating pseudobulbar affect (PBA)? - Dr.Oracle AI, accessed September 4, 2025, https://www.droracle.ai/articles/46828/is-dextromethorphan-effective-in-treating-pseudobulbar-affect-pba
72. Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/26701197/
73. Assessment of Off-label Prescribing Compared With FDA-Approved, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6142962/
74. Combination of Dextromethorphan, Quinidine Reduces Agitation in Alzheimer's Patients, accessed September 4, 2025, https://psychiatryonline.org/doi/10.1176/appi.pn.2015.PP8a2
75. Quinidine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose | Drug Index | Pediatric Oncall, accessed September 4, 2025, https://www.pediatriconcall.com/drugs/quinidine/916
76. Quinidine (oral route, injection route, intramuscular route) - Side effects & dosage - Mayo Clinic, accessed September 4, 2025, https://www.mayoclinic.org/drugs-supplements/quinidine-oral-route-injection-route-intramuscular-route/description/drg-20065770
77. Quinidine: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 4, 2025, https://www.rxlist.com/quinidine/generic-drug.htm
78. High Risk of QT Interval Prolongation and Torsades de Pointes Associated with Intravenous Quinidine Used for Treatment of Resistant Malaria or Babesiosis - PMC, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3421624/
79. High Risk of QT Interval Prolongation and Torsades de Pointes Associated with Intravenous Quinidine Used for Treatment of Resistant Malaria or Babesiosis | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 4, 2025, https://journals.asm.org/doi/abs/10.1128/aac.06396-11
80. Quinidine Advanced Patient Information - Drugs.com, accessed September 4, 2025, https://www.drugs.com/cons/quinidine.html
81. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes, accessed September 4, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2015.12.063
82. Overview of Long QT Syndrome and Torsades de Pointes - Crediblemeds, accessed September 4, 2025, https://crediblemeds.org/healthcare-providers/clinical-overview-long-qttorsades
83. Quinidine Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 4, 2025, https://www.drugs.com/sfx/quinidine-side-effects.html
84. Quinidine: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed September 4, 2025, https://www.webmd.com/drugs/2/drug-12175/quinidine-gluconate-oral/details
85. QUINIDINE AND OTHER TYPE IA ANTIARRHYTHMIC DRUGS - AccessMedicine, accessed September 4, 2025, https://accessmedicine.mhmedical.com/content.aspx?bookid=2284§ionid=248385337
86. Quinidine: MedlinePlus Drug Information, accessed September 4, 2025, https://medlineplus.gov/druginfo/meds/a682396.html
87. Quinidine Uses, Side Effects & Warnings - Drugs.com, accessed September 4, 2025, https://www.drugs.com/mtm/quinidine.html
88. Quinine: not a safe drug for treating nocturnal leg cramps - PMC, accessed September 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4347765/
89. Nuedexta - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021879s014lbl.pdf
90. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/331400/
91. Quinidine | Davis's Drug Guide for Rehabilitation Professionals, accessed September 4, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139023881
92. Quinidine Interactions Checker - Drugs.com, accessed September 4, 2025, https://www.drugs.com/drug-interactions/quinidine.html
93. A Narrative Review on Clinical Trials Showing Contraindicated Drugs With Grapefruit Juice, accessed September 4, 2025, https://etflin.com/article/162
94. Grapefruit–drug interactions - Wikipedia, accessed September 4, 2025, https://en.wikipedia.org/wiki/Grapefruit%E2%80%93drug_interactions
95. Drug Interactions with Grapefruit Juice | BJMP.org, accessed September 4, 2025, https://www.bjmp.org/content/drug-interactions-grapefruit-juice
96. Quinidine – Health Information Library | PeaceHealth, accessed September 4, 2025, https://www.peacehealth.org/medical-topics/id/hn-1476002
97. Quinidine Sulfate Food, Alcohol, Supplements and Drug Interactions, accessed September 4, 2025, https://www.wellrx.com/quinidine-sulfate/lifestyle-interactions/
98. www.drugs.com, accessed September 4, 2025, https://www.drugs.com/food-interactions/quinidine.html#:~:text=Quinidine%20Food%2FLifestyle&text=Grapefruit%20and%20grapefruit%20juice%20can,first%20talking%20to%20your%20doctor.
99. quinidine sulfate tablet, film coated, extended release - RxList, accessed September 4, 2025, https://www.rxlist.com/quinidine-sulfate-drug.htm
100. Label: QUINIDINE GLUCONATE tablet, extended release - DailyMed, accessed September 4, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5023f053-fcc4-4c2c-aa59-9ec198ad185e
101. Quinidine: Pediatric Medication - Memorial Sloan Kettering Cancer Center, accessed September 4, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/pediatric/quinidine
102. Quinidine (PIM 463) - Inchem.org, accessed September 4, 2025, https://www.inchem.org/documents/pims/pharm/quinidin.htm
103. Quinidine - WikEM, accessed September 4, 2025, https://wikem.org/wiki/Quinidine
104. www.mayoclinic.org, accessed September 4, 2025, https://www.mayoclinic.org/drugs-supplements/quinidine-oral-route-injection-route-intramuscular-route/description/drg-20065770#:~:text=Children%E2%80%9430%20to%2040%20mg,increase%20the%20dose%20if%20needed.
105. Quinidine | Division of Cardiology - Washington University in St. Louis, accessed September 4, 2025, https://pediatriccardiology.wustl.edu/items/quinidine/
106. Quinidine Use During Pregnancy - Drugs.com, accessed September 4, 2025, https://www.drugs.com/pregnancy/quinidine.html
107. Dextromethorphan / quinidine (Nuedexta) Use During Pregnancy - Drugs.com, accessed September 4, 2025, https://www.drugs.com/pregnancy/dextromethorphan-quinidine.html
108. Quinidine - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed September 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501089/
109. Quinidine: Drug information, accessed September 4, 2025, https://doctorabad.com/uptodate/d/topic.htm?path=quinidine-drug-information
110. Antiarrhythmics: elimination and dosage considerations in hepatic impairment - PubMed, accessed September 4, 2025, https://pubmed.ncbi.nlm.nih.gov/18027986/